- Home
- ENTX vs EEA Comparison
ENTX vs EEA Comparison
Compare ENTX & EEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- EEA
- Stock Information
- Founded
- ENTX 2010
- EEA 1986
- Country
- ENTX Israel
- EEA Germany
- Employees
- ENTX N/A
- EEA N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- EEA Trusts Except Educational Religious and Charitable
- Sector
- ENTX Health Care
- EEA Finance
- Exchange
- ENTX Nasdaq
- EEA Nasdaq
- Market Cap
- ENTX 67.2M
- EEA 60.8M
- IPO Year
- ENTX 2018
- EEA N/A
- Fundamental
- Price
- ENTX $1.73
- EEA $8.50
- Analyst Decision
- ENTX Strong Buy
- EEA
- Analyst Count
- ENTX 1
- EEA 0
- Target Price
- ENTX $10.00
- EEA N/A
- AVG Volume (30 Days)
- ENTX 127.7K
- EEA 9.2K
- Earning Date
- ENTX 11-08-2024
- EEA 01-01-0001
- Dividend Yield
- ENTX N/A
- EEA 1.92%
- EPS Growth
- ENTX N/A
- EEA N/A
- EPS
- ENTX N/A
- EEA N/A
- Revenue
- ENTX $99,000.00
- EEA N/A
- Revenue This Year
- ENTX N/A
- EEA N/A
- Revenue Next Year
- ENTX N/A
- EEA N/A
- P/E Ratio
- ENTX N/A
- EEA N/A
- Revenue Growth
- ENTX 607.14
- EEA N/A
- 52 Week Low
- ENTX $0.52
- EEA $7.45
- 52 Week High
- ENTX $3.35
- EEA $9.26
- Technical
- Relative Strength Index (RSI)
- ENTX 44.32
- EEA 32.37
- Support Level
- ENTX $1.64
- EEA $8.71
- Resistance Level
- ENTX $1.80
- EEA $8.57
- Average True Range (ATR)
- ENTX 0.09
- EEA 0.16
- MACD
- ENTX -0.01
- EEA -0.03
- Stochastic Oscillator
- ENTX 30.00
- EEA 6.05
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.